TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options for Patients With Recurrent SCLC
Source: Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Recurrent SCLC
Treatment options for patients with recurrent small cell lung cancer (SCLC) include:
Chemotherapy.
Source links and citations
Immunotherapy.
Source links and citations
Immune checkpoint modulation.
Source links and citations
Palliative therapy.
Source links and citations
Phase I and II clinical trials evaluating new drugs, including bispecific T-cell engager (BiTE) immunotherapies.
At the time of recurrence, many patients with SCLC are potential candidates for further therapy.
For patients with recurrent SCLC, immune checkpoint modulation with anti–programmed death-ligand 1 (anti–PD-L1) antibodies may lead to durable responses either as single agents or in combination with cytotoxic T lymphocyte antigen-4 (anti–CTLA-4). Impacts on long-term survival from these approaches are being assessed in randomized trials.
Continue within this section
Preserved source evidence · Not medical advice